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Background and Objectives Platelet function shows significant inheritance that is
at least partially genetically controlled. There is also evidence that the platelet
response is stable over time, but there are few studies that have assessed consis-
tency of platelet function over months and years. We aimed to measure platelet
function in platelet donors over time in individuals selected from a cohort of 956
donors whose platelet function had been previously characterised.
Materials and Methods Platelet function was assessed by flow cytometry, mea-
suring fibrinogen binding and P-selectin expression after stimulation with either
cross-linked collagen-related peptide or adenosine 50-diphosphate. Eighty-nine
donors from the Cambridge Platelet Function Cohort whose platelet responses
were initially within the lower or upper decile of reactivity were retested between
4 months and five and a half years later.
Results There was moderate-to-high correlation between the initial and repeat
platelet function results for all assays (P ≤ 0007, r2 02961–07625); furthermore,
the range of results observed in the initial low and high responder groups
remained significantly different at the time of the second test (P ≤ 00005).
Conclusion Platelet function remains consistent over time. This implies that this
potential influence on quality of donated platelet concentrates will remain essen-
tially constant for a given donor.
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Introduction
Within the general population, several studies have con-
firmed the long-held notion that the response of platelets
to agonists is highly variable, but for an individual, the
level of responsiveness is remarkably consistent over time
[1–5]. The belief that highly characterised platelet func-
tion phenotypes are stable has underpinned the applica-
tion of genomic studies to identify genetic variants
underlying platelet function [6–8].
The recognition that platelet reactivity is at least partly
genetically controlled, and therefore, potentially stable over
time is supported by observations in the Framingham Heart
Study which found that heritable factors played a key role
in aggregation responses [9] and is compatible with the
notion that the interindividual variation in platelet
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parameters such as their count, volume and function is to a
large extent inherited and therefore stable [7, 8, 10–13].
Knowledge that platelet function is consistent over time
has a number of implications. The ability to reproducibly
measure and demonstrate stable platelet function for a
given individual supports the desire to personalise treatment
with antiplatelet therapy after percutaneous coronary inter-
vention [14]. Similarly, demonstration of wide but stable
variation of platelet function between individuals has speci-
fic implications for blood services, as inherent variation in
donor platelet function has already been shown to influence
the quality of platelets donated via apheresis [15]. Further-
more, donor variability has also been suggested as a factor
that influences posttransfusion platelet increments [16].
Many studies of platelet function however only cover
periods of months, and some focus on single agonists, sin-
gle measures of activation or only on individuals defined
as hyper-responsive to specific agonists [1, 2, 5]. Simi-
larly, although variation in platelet function among blood
and particularly platelet donors has been demonstrated
[3, 17], there is a lack of information about the consis-
tency of this variation over time. Our previous study of
both whole blood and plateletpheresis donors demon-
strated wide but consistent interindividual variation in pla-
telet function. It however only assessed reproducibility
after 3 months and did not review the details of blood
donations between the initial and repeat testing [3].
The overall aim of our study was to measure platelet
function in a cohort of individuals over a period of time
which was longer than previously reported, to support the
notion that platelet function within an individual is con-
sistent over time. We achieved this with a panel of 89
established platelet donors whose platelet function was
known to be at either the low or high ends of the normal
range and testing them at intervals between measurements
ranging from 4 months to approximately 5 years. If
observed, demonstration of consistent platelet function
over these periods would add to existing knowledge and
achieve our aims of providing further support to the belief
that this trait is at least partially genetically controlled and
consequently indicating that any association between a
donor’s platelet function and the quality of their donated
platelets would remain a consistent feature. In addition,
the data would support the use of donors with highly char-
acterised platelet function in clinical trials to assess the
role of donor variation on the outcome of transfusions.
Materials and methods
Cohorts and subjects
The subjects for this study were selected from the 956
whole blood or platelet donors in the Cambridge Platelet
Function Cohort [3]. They were recruited over a period of
5 years, from the National Health Service Blood and
Transplant blood donor clinic in Cambridge after gaining
informed, written consent, and were established donors of
platelets by apheresis. The study was approved by the
Huntingdon Research Ethics Committee (Reference num-
ber 05/Q0104/27).
Individuals in the entire cohort of 956 donors were
characterised on the basis of their platelet response to
cross-linked collagen-related peptide (CRP-XL) and ADP,
assessing their activation by flow cytometry, with fibrino-
gen binding and P-selectin (CD62P) expression as markers
representing activation of the glycoprotein IIbIIIa com-
plex and a-granule release, respectively. These tests were
carried out in the presence of aspirin and hirudin, to
block the effects on the platelets of endogenous throm-
boxane A2 and thrombin, respectively, and in the case of
the CRP-XL-stimulated samples, apyrase was added to
block endogenous ADP.
Initial testing of the donors occurred during two peri-
ods. Platelets from donors in the first period, from July to
August 2005, were tested against both agonists using
both activation markers giving four measurements of pla-
telet function. The second recruitment period, between
June 2009 and July 2010, occurred in order to increase
the size of the cohort to provide platelets for use in a
clinical trial investigating possible associations between
the level of platelet responsiveness and the clinical effi-
cacy of transfused platelets (http://www.nhsbt.nhs.uk/
clinicaltrialsunit/current-trials/prompt/index.asp#.Vl7O
t8J_t1E). During this period, fibrinogen binding in response
to both ADP and CRP-XL was measured, but P-selectin
expression was only measured following CRP-XL activa-
tion, giving three platelet function measurements. Comple-
tion of the second recruitment period 5 years after the
initial recruitment began provided the opportunity to retest
donors with a range of different time periods between their
initial and repeat testing. The assays used for the original
testing were repeated to assess the consistency of platelet
function over time.
The 89 platelet donors identified for retesting were
selected for the clinical trial based on the hypothesis that
use of donors with either low or high platelet function
would be most likely to demonstrate potential differences
in clinical outcome in patients. These donors had been
characterised as having platelet reactivity within the
lower or upper decile of overall observed reactivity. The
method for assigning the donors to these low and high
responder groups has been previously described [3].
Briefly, classification involved combining the standard-
ised residuals of the logit-transformed flow cytometry
data for all measurements into a single ranking profile.
High responders were defined as those with the highest
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minimum response, low responders as those with the low-
est maximum. The donors were therefore considered as
having overall platelet function responses that were either
low or high, based on the overall range of responses
observed in the entire cohort. For illustration, Fig. 1
shows where the selected donors lie in relation to the
whole cohort in the distribution of results for the three
assays common to testing all donors.
Of the 89 donors, 66 (28 low responders and 38 high
responders) who had been initially tested between 4 and
20 months earlier had donated an average of eight times
during this period. The remaining 23 (nine low responders
and 14 high responders) were from the first recruitment
period, originally tested between 64 and 68 months earlier
and were described in 2007 [3]. These individuals donated
an average of 49 times between initial and repeat testing.
Characteristics of the 89 donors are shown in Table 1. All
the donors were Caucasians, and none had diabetes.
Blood collection
Blood was drawn prior to apheresis donation, from the
antecubital fossa contra lateral to the one used for routine
donation. A 21-gauge butterfly needle and a Vacuette
tube (Griener Bio one, Stonehouse, UK) were used follow-
ing a standardised protocol. The first 3 ml of blood were
discarded, and a subsequent sample was taken into 32%
sodium citrate for platelet function analysis.
Platelet activation reagents
For platelet activation, CRP-XL (monomeric sequence
GCO[GPO]10GCOG) was prepared as described previously
[18] and was a kind gift from Professor Richard Farndale.
Different batches of CRP-XL were used for the initial and
repeat testing. Due to the instability of the diluted pep-
tide, the reagent was stored in concentrated form at +4°C
and diluted to a working concentration each day. The
same batch of ADP, obtained from Sigma Chemical Co.,
Ltd (Poole, Dorset, UK), was used throughout the study
and stored at -80°C in single-use aliquots.
The inhibitors, aspirin, apyrase and hirudin, were all
from Sigma and were stored at -80°C in single-use ali-
quots until added to the citrated blood during the activa-
tion assays.
The antibodies used for flow cytometry were rabbit
polyclonal FITC-anti-fibrinogen (Dako Ltd, Ely, UK) and a
single batch of PE-anti-CD62P (Bristol Institute for Trans-
fusion Science, Bristol, UK). HEPES-buffered saline (HBS,
014 M NaCl, 5 mM KCl, 1 mM MgSO4, 10 mM HEPES
(sodium salt) pH 74) was used for all dilutions.
Platelet activation measurements using whole
blood flow cytometry
Blood was processed within 10 minutes of venesection.
Aspirin (100 lM) and hirudin (10 U/ml) were added to an
aliquot of citrated blood and 5 ll of this added to 45 ll
of HBS containing CRP-XL (01–05 lg/ml, depending on
batch) or ADP (10-7 M) and either FITC-anti-fibrinogen,
Fig. 1 Platelet function responder groups. Values represent the standard-
ised residuals of the logit-transformed results for ﬁbrinogen binding in
response to ADP stimulation (FA), ﬁbrinogen binding in response to CRP-
XL stimulation (FC) and P-selectin expression following CRP-XL stimula-
tion (PC) for the entire cohort of 956 donors. The cohort excluding the
selected low and high responders is shown as light-grey spheres. Donors
classiﬁed as low responders at ﬁrst testing and still available for repeat
testing as shown as mid-grey spheres and the available high responders
as black spheres.
Table 1 Details of the short-term and long-term follow-up groups
Characteristic Short-term Long-term
Number of donors 66 23
Mean number of donations
between tests (range)
8 (1–22) 49 (4–80)
Number of low responders (%) 28 (42) 9 (39)
Number of high responders (%) 38 (58) 14 (61)
Mean age, years at initial test (SD) 493 (94) 47 (67)
Mean age, years at repeat test (SD) 503 (94) 52 (67)
Sex, female: male 4:62 1:22
Mean body mass index (SD) 274 (41) 280 (35)
Current smoker (%) 6 (9) 1 (4)
Subjects with hypertension (%) 4 (6) 0
Subjects with high cholesterol (%) 5 (8) 4 (17)
Contraceptive pill (%) 1 (2) 0
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or PE-anti-CD62P. For CRP-XL-stimulated samples, apyr-
ase (4 U/ml) was also included in the reaction mixture.
Samples were incubated for 20 minutes at room tempera-
ture, and reactions were then stopped by 100-fold dilu-
tion in formyl saline (02% formaldehyde in 09% NaCl).
Negative controls for the P-selectin antibody were set
using an appropriate isotype control and for antifibrino-
gen using samples incubated with the antibody in the
presence of 10 mM EDTA. Flow cytometric analysis was
carried out on either an EPICS Profile XL (Beckman-Coul-
ter Ltd., High Wycombe, UK) for the initial testing period
or a FC500 flow cytometer (Beckman-Coulter Ltd) for the
second testing period. Platelets were identified by light
scatter, and results were recorded as the percentage of
platelets positive for the relevant activation marker. All
tests were performed in duplicate, and the average result
were used for analysis.
The protocol was as referred to previously [3], with the
exceptions that the final reaction volume was changed to
50 ll, and the final concentration of EDTA to 10 mM.
Statistical analysis
Data were analysed using PRISM versions 4.0c (GraphPad
Software Inc, San Diego, USA). The correlation between ini-
tial and repeat platelet function results was analysed using
Pearson’s correlation, and differences between the responder
groups were compared using an unpaired t-test; P values
less than 005 were considered statistically significant.
Results
Platelet function results
Platelets from both the low and high responder donors
who were followed up over a short term (4–20 months)
were analysed for fibrinogen binding following stimula-
tion with ADP and CRP-XL and for P-selectin expression
following CRP-XL induced activation. As shown in Fig. 2,
the level of reproducibility of the three assays was mod-
erate, with significant correlations being observed
between the original and retest data for all assays
(r2 > 037; P < 00001 for all).
Donors who were followed up for a longer term (64–
68 months) were analysed for both fibrinogen binding
and P-selectin expression measured following stimulation
with CRP-XL and ADP. Again, significant correlations
were observed between the original and retest data for all
four assays (r2 > 029; P ≤ 00073, Fig. 3).
For both groups, it was notable that the ADP results
were more reproducible than those obtained with CRP-
XL, with higher degrees of correlation and lower P-values
(Figs 2 and 3).
Maintenance of low and high responder status
Despite the high degree of correlation between the initial
and retest results, there were some divergence and
Fig. 2 Short-term follow-up (4–20 months): relationship between initial
and repeat platelet function test results. Results for the ﬁrst and repeat
tests are shown. Values represent the percentage of platelets (PLT)
expressing the relevant activation marker. Donors classiﬁed as low
responders at ﬁrst testing are shown as ○ and high responders as M. (a)
Fibrinogen binding following CRP-XL stimulation, (b) P-selectin expres-
sion following CRP-XL stimulation and (c) ﬁbrinogen binding in response
to ADP stimulation (n = 66 donors for all tests).
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regression to the mean. Therefore, we tested whether the
classification of groups as low and high responders
remained valid over time.
At the initial testing, results from all assays were sig-
nificantly different between the two responder groups. On
retesting the donors with a shorter-term follow-up,
between 4 and 20 months later, the differences between
responder groups for the three tests performed remained
significant. Similarly, for the long-term donors, retesting
more than 5 years later again revealed significant differ-
ences between the two responder groups for all four tests
at both time-points (Table 2).
Discussion
To date, studies of variation in platelet function that have
included monitoring function over time have demon-
strated consistency over periods ranging mainly from
weeks to months, with a small number being confirmed
after an average of 19 months [1–3, 5]. These observa-
tions are in keeping with the notion that this quantitative
trait is strongly genetically controlled.
We have added to the data supporting this assumption
by expanding our previously described Cambridge Platelet
Function Cohort [3] to include almost one thousand
donors and subsequently retesting a subset of individuals
sampled from the tail ends of the normal distribution of
platelet function, and which were considered as either
low or high responders.
By assessing volunteers twice, with test intervals
between 4 and 68 months and after making between
one and 80 donations, we were able to demonstrate con-
sistency of platelet functional responses within individu-
als. Furthermore, the significant differences in platelet
function between low and high responders at the time
of initial enrolment were maintained. These observations
Fig. 3 Long-term follow-up (64–68 months):
relationship between initial and repeat platelet
function test results. Results for the ﬁrst and
repeat test are shown. Values represent the
percentage of platelets (PLT) expressing the
relevant activation marker. Donors classiﬁed as
low responders at ﬁrst testing are shown as ○
and high responders as M. (a) Fibrinogen
binding following CRP-XL stimulation (n = 23
donors), (b) P-selectin expression following
CRP-XL stimulation (n = 21 donors), (c)
ﬁbrinogen binding in response to ADP
stimulation (n = 23 donors) and (d) P-selectin
expression in response to ADP stimulation
(n = 22 donors).
Table 2 Result ranges for low and high responder donorsa
Group Short term (n = 66) Long term (n = 23)
Test occasion Initial Repeat Initial Repeat
Responder group Low High Low High Low High Low High
Agonist (activation marker)
CRP-XL (Fibrinogen) 91 – 36 389 – 101 222 – 132 439 – 153 237 – 106 615 – 108 166 – 82 396 – 118
CRP-XL (P-selectin) 179 – 77 555 – 99 314 – 141 522 – 167 318 – 91 729 – 101 268 – 110 491 – 138b
ADP (Fibrinogen) 182 – 66 615 – 128 212 – 108 451 – 131 142 – 59 408 – 83 189 – 80 445 – 121
ADP (P-selectin) nt nt nt nt 71 – 29 186 – 41 138 – 35 240 – 58
nt, not tested.
aResults are the percentage of platelets expressing the relevant activation marker, and values are mean – 1SD.
The difference between low and high groups was all signiﬁcant with P < 00001, except forb where P = 00005.
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imply that regular platelet donation does not have a
major long-term impact on platelet function in
established donors. They do not however exclude tempo-
rary effects immediately following donation. For exam-
ple, we have previously shown that platelets remaining
in the donor’s circulation after apheresis donation were
generally less responsive to ADP than before donation
[15].
Although the initial and second assay results correlated
significantly, they were however not identical. A ten-
dency for regression to the mean, where results which are
low or high at first measurement tend to be closer to the
average result on second measurement, may have con-
tributed to differences in results. In addition, technical
and operational variables between the two occasions of
testing could have influenced results. The greater repro-
ducibility of the ADP results compared with the CRP-XL
results for example probably reflects batch variability for
CRP-XL, whereas the same batch of ADP was used for all
tests.
Furthermore, although it is believed that up to 70%
of variation in platelet responses is inherited [8, 9, 19],
circadian variations, environmental factors such as diet,
smoking and exercise can also contribute to small varia-
tions platelet function [20]. These factors were not con-
trolled within the current study. The ability to improve
the reproducibility of platelet function assay results by
regulating factors such as food, alcohol intake and exer-
cise was highlighted by previous observations that
within an individual, variability in platelet function
could be decreased by standardising these parameters
[21].
Demonstration of wide but stable variation of platelet
function may have implications for transfusion therapy.
Previous studies have shown the degree of activation
induced by collecting platelets via apheresis procedures
varies considerably between donors [22, 23]. We have
demonstrated that the inherent platelet responsiveness of
individual donors may contribute to platelet quality, with
highly activated platelets being obtained from high
responder donors [15]. Thus, variation in quality of plate-
let concentrates is at least partly donor related, and as
such our current study implies that this will remain a
consistent feature for a given donor.
The clinical implications of the current observations for
patients receiving platelet transfusions however remain
unclear. There is still debate about the ability of in vitro
platelet function measurement to predict in vivo platelet
recovery, survival and function. Some reports have sug-
gested that expression of activation markers such as
CD62P in platelet concentrates correlates inversely with
posttransfusion survival [24], while others have failed to
find such a relationship [25]. Data from the recently
completed semi-randomised, controlled clinical trial to
assess whether the outcome from platelet transfusions dif-
fers according to the platelet function characteristics of
the donor are currently being reviewed (http://
www.nhsbt.
nhs.uk/clinicaltrialsunit/current-trials/prompt/index.asp#.
Vl7Ot8J_t1E).
Overall, we have shown that the wide variation of pla-
telet function among blood donors remains consistent
over periods of up to 68 months of regular donations.
This observation is compatible with the notion of there
being a high level of heritability for this quantitative pla-
telet trait, and this may have implications for platelet
transfusions, as well as wider considerations in relation to
haemostasis and thrombosis.
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